Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study
Open Access
- 15 May 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (5), 1488
- https://doi.org/10.3390/jcm9051488
Abstract
Colchicine has been effectively used to prevent acute flares in patients with gout, but drug-related adverse events have frequently occurred. We investigated whether colchicine therapy with febuxostat is associated with hepatotoxicity in gout patients. Gout patients treated with (n = 121) or without (n = 57) colchicine were enrolled upon initiating febuxostat as a urate-lowering treatment, and clinical and laboratory data at diagnosis were compared. Logistic regression analysis was performed to evaluate the risk factors related to hepatotoxicity. Median age of the with-colchicine and without-colchicine groups was 51.0 (37.0–62.0) and 56.0 (43.5–68.5) years, respectively. During the three months of febuxostat prescription, the prevalence of hepatotoxicity was 13/121 (10.9%) in the with-colchicine group and 4/57 (7.0%) in the without-colchicine group, without statistical significance. The rate of colchicine use was not different between the study subjects with or without hepatotoxicity (76.5% vs. 67.1%, p = 0.587). Pre-existing liver disease was significantly associated with increased risk of hepatotoxicity after febuxostat treatment (odds ratio, 4.083; 95% confidence interval, 1.326–12.577; p = 0.014). Colchicine may be safely used as a prophylactic agent for gout patients with febuxostat. However, upon initiating febuxostat, it is recommended to monitor the development of acute liver injury in gout patients with underlying liver disease.Keywords
This publication has 30 references indexed in Scilit:
- Clinical and Biochemical Profile of Tuberculosis in Patients with Liver CirrhosisJournal of Clinical and Experimental Hepatology, 2015
- Inpatient Gout: A ReviewCurrent Rheumatology Reports, 2014
- Mechanism of Action of Colchicine in the Treatment of GoutClinical Therapeutics, 2014
- Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flaresInternational Journal of Rheumatic Diseases, 2014
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Assessment of the Association Between Colchicine Therapy and Serious Adverse EventsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitorsArthritis & Rheumatism, 2011
- Clinical features and risk factors of postsurgical goutAnnals Of The Rheumatic Diseases, 2007
- Acute Myopathy in a Patient with Concomitant Use of Pravastatin and ColchicineAnnals of Pharmacotherapy, 2005
- Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in MenNew England Journal of Medicine, 2004